Job Offer: CINBIO 26. Postdoc Researcher on Biomass and Sustainable Development


Profile: The Biomedical Research Center (CINBIO) offers one full-time interim postdoctoral position to a highly motivated and qualified researcher on “extraction and purification of bioactive products from biomass”, related to the area of Biohealth and Active Ageing, in the group of Biomass and Sustainable Development, based in OurenseTime frame: initially for 7,5 months (starting on march 2018), and may be continued.

Find here the final resolution on this recruitment process. CINBIO 26 EQ2-Final Resolution 

Read more

Dr. David Posada involved in Marie Curie Network.

The Innovative Training Networks (ITN) bring together universities, research centres and companies from different countries worldwide to train a new generation of researchers, in this case, Computational Oncology Researchers. This project is funded by European Union with 3.8mill€.

Project: “CONTRA“, Computational ONcology TRaining Alliance. ID number: 766030, “H2020-EU.1.3.1. – Fostering new skills by means of excellent initial training of researchers

CONGRATULATIONS to David Posada’s Group, Evolutionary and Biomedical Genomics, that is directly involved in these “Early Stage Researcher” projects:

ESR 11: Estimation of tumour growth rates from NGS data

ESR 12: Mutational patterns and models within tumours.  

More information about itn-CONTRA.


Interview with David Posada. PI of Evolutionary Genomics group.

Doctor in Zoology, Full Professor of Genetics at the University of Vigo and coordinator of the Evolutionary Genomics Group (XB5) for CINBIO, David Posada González is the only Galician researcher to be awarded a Consolidator Grant, given by the European Research Council (ERC) in 2013. In 2003 he received a Ramón y Cajal grant, and in 2007 a Starting Grant, also given by the ERC. In addition, he is regarded as an ISI Highly Cited Researcher, according to Thomson Reuters, since 2003.


One of the lines of research of your group was awarded a Consolidator Grant by the ERC and it focuses on the creation of a theoretical and methodological framework allowing better comprehension of the evolution of carcinogenic tumour cells. What results do you hope to find in this area?

PHYLOCANCER is an ambitious 5 year project with 2 clear objectives: on one hand, to fine tune techniques for the study of individual genomes in tumour cells, and the development of bioinformatic methodologies for the mass analysis of genomic data. On the other, the generation of knowledge about evolutionary parameters in the life of a tumour, its history and how its characteristics develop (metastasis, growth rate, etc.) in each individual patient.


The results of PHYLOCANCER will offer new computational tools to the scientific community for the mass analysis of genomic data, and information about the evolutionary history of cancer, which could contribute to future improvements in fully personalized diagnosis and prognosis for patients with all tumour types.


This is a multidisciplinary study in which we collaborate with various regional hospitals (Hospital Álvaro Cunqueiro and Meixoeiro de Vigo and USC Hospital University Complex, Santiago de Compostela), and the focus is on two types of cancer: colorectal  cancer and chronic lymphocytic leukemia.


In addition to being given a Consolidator Grant for your PHYLOCANCER project, in 2007 the ERC awarded you a Starting Grant for the PHYLOGENOM project. What was the subject matter of the project and what are the main conclusions you drew from it?

PHYLOGENOM is based on the development of a general methodology for genome evolution in any type of sexual organism, those which produce offspring from reproduction between a male and female. This project offered us the chance to develop scientific knowledge about the evolution of DNA in this type of organism, but above all methodological tools to measure it and characterize it statistically.


Bioinformatics is a key aspect of your group and of the research projects you carry out. In this context you have developed a number of open to use applications for the scientific community. Which of them would you highlight for its value?

Bioinformatics has been key for the evolution and relevance of our research group. We have developed multiple techniques and methodologies which are today used by scientists all over the world in their data analysis routines but I would perhaps higlight ModelTest, which I developed in 1998 during my phD, and whose descriptive article, with more than 20,000 citations, is one of the top 100 most cited articles of all time, according to “Nature” journal. ModelTest is a methodology which, based on biostatistical calculations, allows the best DNA evolution model to be selected for a particular set of scientific data and which has become a standard by which to justify the model used in phylogenetic research studies.


There are no doubts about your potential in scientific production, with more than 130 articles appearing in high impact publications, such as Nature. In addition, you are recognized as an ISI Highly Cited Researcher. How do you assess your position nationally and internationally? What other indicator about your group would you highlight?

This recognition obviously makes us a group of excellence internationally, but it also means that the methodologies that we develop are useful and facilitate research all over the world.


This prestige on an international level means that regionally we are one of the best placed to attract international talent. In our group you can find researchers from Germany, Switzerland, Portugal, etc…


In addition, another of the key aspects of our group is its cross-disciplinary nature. This enriches our lines of research immensely with many different complementary perspectives, such as knowledge in chemistry, biology and informatics.


Beyond the multidisciplinary environment and the ease of synergies between research groups, what advantages does CINBIO offer as a group? And what about for you as a researcher?

Without doubt, CINBIO is an ecosystem which strengthens the establishment of synergies and collaborations between complementary research groups, allowing our projects to be more global and more comprehensive, tackling the same issue from different angles.


CINBIO is also an opportunity to access cutting-edge technologies and generate a knowledge “biocluster”, which joins the capacities of different groups together and makes us all more competitive internationally and allows us to take on more challenging and more complete projects.

CINBIO 24 Responsible of the Management Unit (Singular Centre). Process resolution.

The CINBIO offers one position as Responsible of the Management Unit (Singular Centre). 

Application deadline:  15 October 2017 (16:00 hours, local time).

The documents should be sent to Indicate the Reference number.

Complete information: CINBIO 24 Responsible of the Management Unit .

The Human Resources Commission publishes the CINBIO 24 Admitted candidates final list .

Deadline for score revision: 21 November 2017. (

CINBIO 24. Provisional scores.

CINBIO 24. Scores and interviews. Final list

CINBIO 24. Interviews. Provisional scores.

CINBIO 24. Process Resolution

CINBIO 25. Cancer Genomics. Predoctoral position . Process resolution.

The CINBIO offers one position as predoctoral student. Line of research: Cancer Genomics. 

Application deadline:  15 October 2017 (16:00 hours, local time).

The documents should be sent to Indicate the Reference number.

Complete information: CINBIO 25. Cancer genomics. Predoctoral position

CINBIO 25. Admitted candidate. Final list.

CINBIO 25. Provisional scores.

CINBIO 25. Process resolution

Interview with Francisco Javier Rodríguez Berrocal. Molecular Biomarkers.


Francisco Javier Rodríguez Berrocal is a Full Professor of Biochemistry and Molecular Biology and secretary of the department of Biochemistry, Genetics and Immunology at the University of Vigo. In addition, he is also Principal Investigator for CINBIO’s Molecular Biomarkers group (BB1).

The BB1 group is multidisciplinary and it contains three different teams: Protein Biochemistry, Glycoproteomics, and Human Genetics. Despite this spread, they share a common aim: to find new genetic, proteic or glycidic markers, with the view of their potential application to various human pathologies.

What are the main lines of research being worked on, both individually and as a whole?

The three groups are working on the use and development of biological molecules as diagnostic, prognostic and disease monitoring markers in both humans and animals. We apply them to a wide range of diseases, from prevalent diseases such as cancer to rarer diseases such as ciliopathies.

How do you articulate the cross-disciplinary aspect of the group? In what way does working allow that in your day to day research? Could you give an example of the most transverse project in which all three teams participate?

By having a basic common goal, which is our joint work with biomarkers. Each group has a Lead Researcher and I am coordinator for the whole group (BB1). In day to day functioning we share biochemical techniques and equipment. For instance, methylation studies are particularly important and can be applied to various projects.

With regard to results transfer, you have a remarkable track record to date. What milestones would you highlight in this area? 

We have been producing research contracts for companies such as CZVeterinaria for the past number of years, and we put together a high number of reports every year to facilitate the diagnosis of ciliopathies in different hospitals. The three groups have all obtained patents, and 5 out of 6 senior researchers in the group are shareholders in the INBIOGAL spin-off company (Biological Research of Galicia).

Meanwhile, the group has had numerous collaborations with research groups both nationally and internationally. Which of these collaborations would you highlight in particular?

I think our collaboration with research groups from Barcelona, Alicante and the Canary Islands is one of the most important we have been involved in. In this project we developed an Applied Research Program for cancer diagnosis, lasting 5 years and funded by the Asociación Española Contra El Cáncer with 1.200.000 €.

What would you say are the main milestones that you have reached as a group on an international level? 

We do not have a specific relevance on an international level, but the group’s track record both in publications and in projects, contracts and patents, has led to 3 of the 6 senior researchers being made Full University Professors, and 2 have obtained the accreditation allowing them to become one.

CINBIO is a multidisciplinary ecosystem which you have been a part of since its beginnings. Which of CINBIO’s strengths would you highlight? To what extent does it help your competitiveness as a research group?

On the one hand, CINBIO is a “melting pot”, where groups offer new ideas and methods to projects that we have all been developing for years. On the other hand, it gives us much more visibility, and the possibility of obtaining aid together, aid to which individually we would not have access.



1 2 3 4 5 21